A comparison of Zoladex® and DES in the treatment of advanced prostate cancer: Results of a randomized, multicenter trial | Zendy

Citrin Dennis L. | Zendy; Resnick Martin I. | Zendy; Guinan Patrick | Zendy; AlBussam Nazar | Zendy; Scott Mark | Zendy; Gau Timothy C. | Zendy; Kennealey Gerard T. | Zendy

Premium

A comparison of Zoladex® and DES in the treatment of advanced prostate cancer: Results of a randomized, multicenter trial

Author(s) -

Citrin Dennis L.,

Resnick Martin I.,

Guinan Patrick,

AlBussam Nazar,

Scott Mark,

Gau Timothy C.,

Kennealey Gerard T.

Publication year - 1991

Publication title -

the prostate

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.295

H-Index - 123

eISSN - 1097-0045

pISSN - 0270-4137

DOI - 10.1002/pros.2990180206

Subject(s) - prostate cancer , medicine , randomized controlled trial , prostate , oncology , cancer , gynecology , prostate disease , urology

This open, prospective study was conducted to compare ZOLADEX® (goserelin acetate implant) and diethylstilbestrol (DES) in the treatment of stage D2 prostate cancer. Sixtyseven patients were allocated to receive 3.6 mg of ZOLADEX® every 28 days by subcutaneous injection (n=48) or 3 mg of DES daily by oral administration (n=19). Median serum levels of testosterone were reduced to castrate levels (<50 ng/dl) within one month of therapy in each group and remained so for up to 120 weeks. According to modified criteria of the National Prostatic Cancer Project, 88% of patients in the ZOLADEX® group and 84% in the DES group were objective responders. Time to treatment failure and survival were not significantly different between groups, yet the confidence limits for the hazard ratios were wide. ZOLADEX® was better tolerated than DES. We conclude that ZOLADEX® is an alternative to DES in patients with stage D2 prostate cancer.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research